Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Average Rating of “Strong Buy” from Analysts

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been assigned an average rating of “Strong Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a buy recommendation and four have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is C$5.58.

A number of research firms have recently weighed in on MDP. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus lifted their price objective on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th.

Medexus Pharmaceuticals Price Performance

MDP stock opened at C$4.29 on Tuesday. The company’s 50 day simple moving average is C$3.04 and its 200-day simple moving average is C$2.66. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$4.60. The firm has a market capitalization of C$105.23 million, a PE ratio of 85.80 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.